Comment from The Somatic Cell Genome Editing Consortium

Summary: The NIH Somatic Cell Genome Editing (SCGE) Consortium, an NIH Common Fund program, supports the proposed guidance but requests greater flexibility regarding the "well-characterized" natural history of diseases. They argue that for rare and ultra-rare diseases, the agency should accept retrospective data because prospective studies may be impossible or cost-prohibitive.